about
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancerCetuximab and chemotherapy as initial treatment for metastatic colorectal cancerCetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusDNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancerQuality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).Report from the OECI Oncology Days 2014Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line settingSystemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.Germline genetics of cancer of unknown primary (CUP) and its specific subtypesAccomplishments in 2008 in the management of curable metastatic colorectal cancer.EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients.Comparison of histopathological and gene expression-based typing of cancer of unknown primary.Neoadjuvant chemotherapy for non-/resectable metastases.Colorectal liver metastases: an update on palliative treatment options.Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis.[Current medicinal treatment of metastasized colorectal carcinoma].[Diagnosis of and therapy for hepatocellular carcinoma].[Principles of postoperative therapy in rectal carcinoma].[New therapy options in colorectal carcinoma].Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.On prejudice and facts and choices.Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.Acute ischaemic stroke and myocardial infarction after chemotherapy with vinorelbine for non-small cell lung cancer: a case report.Immunolocalization of lamins and nuclear pore complex proteins by atomic force microscopy.An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
P50
Q26743883-584194F7-5E7F-4EB9-AAB6-CE875D81E8C7Q28240089-0A2C3619-DDD1-45DF-8191-B317EF770FC2Q29619648-AC9DFD53-BD9C-4BBF-AEDB-D5426646917CQ30837199-883650E3-97A3-4A16-968C-ED28A41FE7A4Q33614301-06D0DCBA-048C-4E2A-B1DF-A1481A6B7630Q34094855-CFEA17D8-7AC1-489D-AA79-7735A876DA62Q34468886-BC9A0746-0A42-4179-B35A-B28C1D5D23A4Q34644867-B96A743B-FCED-45E2-B618-4C7BCD0153C8Q34660081-64B31D33-0E00-4245-B993-6AF22CC6E42DQ35002560-B67ACD74-4A07-4494-BE62-84BD1343B27CQ36295068-9F2EC021-B5F8-465A-8FE6-79D9C33C6E70Q36882835-7F954C90-9C1F-45D1-BB2B-06E9D022AD82Q37225491-FAB82476-A7E8-4C1F-8213-2533628619A0Q37468824-36A201AB-F437-477D-86C1-D9C95E1B30EEQ37640438-F4C15410-F068-49A8-BBD3-FBB12430B010Q37655244-4505725A-AF37-41A9-9EAB-140DE96E07FEQ37937930-F5061CB7-645B-4A8B-9E97-1AC9A4B20EA9Q37998026-7212329D-A465-441B-9492-2F54922AE812Q38161359-611CD581-8BDF-45D7-ACBA-58DDCE3C8AADQ38198804-7A0BE212-64AB-4A5F-B915-B0376972120FQ38920659-5361F611-D6AC-416A-B12F-D374552E1EA7Q39117028-FC70D865-B82B-4DE4-ACF5-5C568FB72300Q40601874-135BCC31-0504-4B9E-A50B-22F749E61267Q40967878-D9C4414A-0997-43D9-A590-E5C78F2E1969Q43006999-A465B051-C7CE-4ACD-A677-D73AB00C6C20Q44481786-B56154CE-7073-412C-96C0-1EDAB346F308Q44739775-F89F0964-7CFC-4BA5-A749-95387921D107Q44787500-13611520-CC1B-4D7D-A1E4-2B88D8033916Q45287822-6E85F6A6-FC33-4AB1-A235-7D05798B2D52Q46047701-B7E14CE6-D424-462F-BE52-58EF52E8C759Q46047900-8B3D1C89-6CB3-466A-822B-EB4238CFA52FQ46816802-301009C7-FDB2-4E1E-944E-D21A67C5FE0EQ46905128-24F5023A-B8D6-41F8-9685-B21EA6E15FEFQ47202956-FCC31F64-27DA-40DB-B100-CD710908E098Q47425582-595D62EA-F12F-4B02-BCD9-09602B11BEB0Q48016450-03A76F24-A1D3-4D1E-BEFD-4C4EA846CCA3Q48379921-D493A5F0-7E81-4939-B10F-63DCE0EC4444Q49042422-D2B3E6A4-1530-4BA0-85B8-211C6F1343E7Q49635325-3EDC8814-F4AB-40EC-BAAD-E2D7B1C50FB9Q50984388-3705CE35-2566-489F-BA2D-2B5076885B1C
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Gunnar Folprecht
@ast
Gunnar Folprecht
@de
Gunnar Folprecht
@en
Gunnar Folprecht
@es
Gunnar Folprecht
@nl
Gunnar Folprecht
@sl
type
label
Gunnar Folprecht
@ast
Gunnar Folprecht
@de
Gunnar Folprecht
@en
Gunnar Folprecht
@es
Gunnar Folprecht
@nl
Gunnar Folprecht
@sl
prefLabel
Gunnar Folprecht
@ast
Gunnar Folprecht
@de
Gunnar Folprecht
@en
Gunnar Folprecht
@es
Gunnar Folprecht
@nl
Gunnar Folprecht
@sl
P227
P101
P1053
F-8638-2011
P106
P21
P214
4216151656237308400000
P227
1150889195
P31
P3829
P496
0000-0002-9321-9911
P7859
viaf-4216151656237308400000